Search company, investor...

Denali Therapeutics

denalitherapeutics.com

Founded Year

2015

Stage

IPO | IPO

Total Raised

$347M

Date of IPO

12/8/2017

Market Cap

4.07B

Stock Price

29.97

About Denali Therapeutics

Denali Therapeutics (NASDAQ: DNLI) is a biotechnology company focused on the discovery and development of therapies for patients with neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, ALS, and others. It pursues treatments by assessing genetically validated targets, engineering delivery, and guiding development through biomarkers that demonstrate target and pathway engagement. The company was founded in 2015 and is based in South San Francisco, California.

Headquarters Location

161 Oyster Point Blvd

South San Francisco, California, 94080,

United States

Missing: Denali Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Denali Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Denali Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Denali Therapeutics is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

838 items

Denali Therapeutics Patents

Denali Therapeutics has filed 1 patent.

The 3 most popular patent topics include:

  • Neurological disorders
  • Prodrugs
  • Rare diseases
patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/27/2020

8/30/2022

Pyridines, Crystallography, Monoclinic minerals, Stimulants, Designer drugs

Grant

Application Date

11/27/2020

Grant Date

8/30/2022

Title

Related Topics

Pyridines, Crystallography, Monoclinic minerals, Stimulants, Designer drugs

Status

Grant

Latest Denali Therapeutics News

How The Parts Add Up: IYY Targets $113

Nov 10, 2022

Nasdaq By Bnk Invest Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Dow Jones U.S. ETF (Symbol: IYY), we found that the implied analyst target price for the ETF based upon its underlying holdings is $112.78 per unit. With IYY trading at a recent price near $91.47 per unit, that means that analysts see 23.29% upside for this ETF looking through to the average analyst targets of the underlying holdings. Three of IYY's underlying holdings with notable upside to their analyst target prices are Beam Therapeutics Inc (Symbol: BEAM), Denali Therapeutics Inc (Symbol: DNLI), and Qualtrics International Inc (Symbol: XM). Although BEAM has traded at a recent price of $37.88/share, the average analyst target is 135.54% higher at $89.22/share. Similarly, DNLI has 131.31% upside from the recent share price of $26.84 if the average analyst target price of $62.08/share is reached, and analysts on average are expecting XM to reach a target price of $17.69/share, which is 77.94% above the recent price of $9.94. Below is a twelve month price history chart comparing the stock performance of BEAM, DNLI, and XM: AD

Denali Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Denali Therapeutics Rank

Denali Therapeutics Frequently Asked Questions (FAQ)

  • When was Denali Therapeutics founded?

    Denali Therapeutics was founded in 2015.

  • Where is Denali Therapeutics's headquarters?

    Denali Therapeutics's headquarters is located at 161 Oyster Point Blvd, South San Francisco.

  • What is Denali Therapeutics's latest funding round?

    Denali Therapeutics's latest funding round is IPO.

  • How much did Denali Therapeutics raise?

    Denali Therapeutics raised a total of $347M.

  • Who are the investors of Denali Therapeutics?

    Investors of Denali Therapeutics include Baillie Gifford & Co., F-Prime Capital, Alaska Permanent Fund, ARCH Venture Partners, Flagship Pioneering and 3 more.

  • Who are Denali Therapeutics's competitors?

    Competitors of Denali Therapeutics include Amylyx Pharmaceuticals and 6 more.

Compare Denali Therapeutics to Competitors

EnClear Therapies Logo
EnClear Therapies

EnClear Therapies develops a treatment device to stop the progress of neurodegenerative diseases.

OptoCeutics Logo
OptoCeutics

OptoCeutics develops medical light that can restore the neuronal activity of Alzheimer's patients and reduce plaque accumulation, which can lead to the development of new medical technologies. The technology is based on known gamma light therapy research, but combines the light in a new way that the flickering is non-perceptible and thus not hindering vision or causing discomfort. The firm was founded in 2018 and is based in Copenhagen, Denmark.

C
Cava Healthcare

Cava Healthcare is focused on enhancing optimal health by predicting, preventing and alleviating diseases.

R
ROXRO Pharma

Roxro Pharma is an early-stage specialty pharmaceutical company dedicated to identifying, licensing, and developing compounds in specialized disease areas with significant sales potential, such as pain management. Roxro will pursue product development with the objective of commercializing these products. Niche products will not be developed by major pharmaceutical companies because they will not fuel their growth requirements. Foreign and biotechnology companies with compounds that have a limited sales potential will not be partnered with major pharmaceutical companies. Therefore there are a number of products not being developed even though they are efficacious, safe and satisfy an unmet medical need.

S
Synapsin Pharmaceuticals

SYNAPSIN is developing therapeutic strategies for the treatmentand prevention ofneurodegenerative disorders such as Alzheimer's disease (AD),Parkinson's disease, Amyotrophic Lateral Sclerosis (ALS), and spinal cord injury.

N
Neorphys

Neorphys is a specialty pharma company focusing on safe pain relief, especially visceral pain management.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.